Www.aids2014.org The potential role of HIV self-testing within pre-exposure prophylaxis implementation Cheryl Case Johnson World Health Organization, HIV.

Slides:



Advertisements
Similar presentations
HIV Counselling and Testing
Advertisements

The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Factors Associated with Potential Exposure to and Transmission of HIV in a Probability Sample of Men Who Have Sex with Men Devon D. Brewer Matthew R. Golden.
Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Washington D.C., USA, July 2012www.aids2012.org Economic Evaluation of the National Program to Prevent Mother-to-Child Transmission of HIV in Ghana.
ASSESSMENT OF POSSIBLE OUTLETS FOR DISTRIBUTION OF HIV ORAL SELF-TEST KITS IN KENYA J. Okal 1, F. Obare 2, J. Matheka 1, W. Tun 3 1 Population Council,
Getting from Point A to Point B: What it means to bring HIVST to market Petra Stankard Technical Advisor 22 July 2014.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Implications for Countries: Critical Issues in Service Delivery and Decision Making Dr. Yogan Pillay Deputy.
Unit 5: IPT Isoniazid TB Preventive Therapy
The potential and challenges of ARV-based HIV prevention: An overview
HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.
Preliminary findings of a routine PMTCT Option B+ programme in a rural district in Malawi Rebecca M. Coulborn 1, Laura Triviño Duran 1, Carol Metcalf 2,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Module 14: Isoniazid Preventive Therapy Programme.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington.
Closing the policy implementation gap Dr Mickey Chopra UNICEF, New York.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Translating the Vision Towards Universal Access Dr Zengani Chirwa.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
The policy development for introducing of the oral fluid based rapid HIV test kit in Thailand Writers in the 2009 Write Workshop (WHO Bulletin)
LINKAGE OF IDENTIFIED CASES TO HEALTH FACILITIES SERVICE PROVISION TO KEY POPULATIONS KABUSUNZU HC.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
Division of HIV/AIDS Prevention CDC-RFA-PS
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Scaling-up male circumcision programmes in the Eastern and Southern Africa Region Country update meeting HIV Testing and Counseling and Male Circumcision.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Task Shifting in Malawi around delivery of antiretroviral therapy Anthony D Harries “The Union” Paris, France.
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Cleanliness Champions: Evaluation of impact on HAI in NHSScotland Professor Jacqui Reilly HPS.
WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.
IAS Policy and Advocacy priority on Treatment as Prevention Carlos F. Cáceres Multidisciplinary Research on ARV-based Prevention 30 June 2013 Kuala Lumpur.
HIV Testing in Medical Settings Mark Thrun, MD Denver Public Health
HIV Testing for TB Patients in the Context of ART Scale-Up - Barriers to Implementation Kevin M. De Cock, MD CDC Kenya Geneva, February 14, 2005.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
GLOBAL TB PROGRAMME Systematic screening for active TB – operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme.
Effective HIV & SRH Responses among Key Populations Module 3: Engaging Key Populations with HIV and SRH Services.
CATHERINA JEMMOTT NOVEMBER 26TH, health districts 7 district health teams 52 health centre/clinics 2 district hospitals Main hospital in Roseau.
Strategies for increasing the uptake of services to prevent mother-to-child transmission (PMTCT) of HIV: the FHI360/Nigeria experience R.Abdul-Hadi, W.O.
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
Situation Analysis Toolkit Step 3: Summary Findings APRIL 2016 This toolkit is designed to help implementers plan for introduction and roll out of oral.
UNITAID PSI HIV SELF-TESTING AFRICA WHEN THE RUBBER MEETS THE ROAD: Moving Self-Testing from a Theory to a Reality for Africa DESIGNING SAFE, ACCEPTABLE.
ACTIVITY-BASED COSTING (ABC)
Treatment as prevention: policy and programmatic considerations
PrEP Scale Up in Kenya: Bridge to Scale Project
Implementing and scaling up HIV self testing in Kenya
Module 4 (e) Pregnancy and Breast Feeding
UNITAID PSI HIV SELF-TESTING AFRICA
TB- HIV Collaborative activities in Romania- may 2006 status
HIV and the ART of Prevention
PrEP and Key populations: WHO guidelines & recommendations
PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.
“Time to Focus: Doing things better and differently for key populations” Partner notification HIV Self Testing and Social Network Testing Dr Irene.
Dr Van Nguyen World Health Organization AIDS July 2018
The cost-effectiveness of HIV pre-exposure prophylaxis in high-risk men who have sex with men and transgendered women in Brazil Paula M. Luz, Ben Osher,
Amsterdam, Netherlands 26 July 2018
Illustrative Cluster Detection and Response Strategy
Partner notification services - 101
Surmounting PrEP delivery challenges through adaptation of implementation guidelines: lessons learned from HIV care clinics in Kenya Elizabeth M. Irungu,
PrEP in Brazil: 18 months of implementation as a public health policy
PrEP Implementation in Vietnam
Dr Paul Mee – London School of Hygiene and Tropical Medicine
Dismas Gashobotse, MD FHI 360/LINKAGES, Burundi
Presentation transcript:

The potential role of HIV self-testing within pre-exposure prophylaxis implementation Cheryl Case Johnson World Health Organization, HIV Department Geneva, Switzerland Abstract Number: TUAC0101

Pre-exposure prophylaxis (PrEP) –Strong recommendation for MSM * –Conditional recommendation for other populations** –Prevention strategy for serodiscordant couples (SDCs)** Daily oral ARVs for HIV negative persons to prevent acquisition *WHO Consolidated KP Guidelines, 2014; **WHO Guidelines for PrEP Demonstration Projects, New WHO recommendations:

PrEP demonstrations underway, but questions remain: Who should take PrEP? How should it be delivered? How much does it cost & how can costs be reduced? Pre-exposure prophylaxis (PrEP)

Cost of Re-Testing Recommended every 3 months (CDC) for HIV negative individuals on PrEP Can burden health workers & facilities Can burden patients Risk of Not Re-Testing Potential seroconversion and drug- resistant virus Pre-exposure prophylaxis (PrEP)

What is HIV self-testing (HIVST)? Positive results need confirmation Source: WHO March 2014 supplement to ARV Guidelines

Many possible HIVST models* Potential models with varying levels of support, access and distribution or initiation Examined 2 facility-based models: Supervised facility-based HIV self-testing Unsupervised HIV self-testing alternated with facility-based testing Source: WHO March 2014 supplement to ARV Guidelines

Partner’s Demonstration Project: Thika, Kenya Open-label PrEP for SDC study data used for preliminary costing exercise* HIVST sub-study: –Between quarterly clinic visits for PrEP prescriptions & HIV testing –HIVST training & distribution of kits for home use –Examining HIVST uptake, preferences etc. *Ngure, K et al. Uptake of HIV Self-testing among people receiving PrEP in Kenya R4P, 2014 [A ]

Estimating the annual cost of retesting Estimates based on 100 clients in 1 st year of PrEP programme: Commodities (rapid test kits, supplies), Human resources: 30 minutes counselling per facility test, 30 minutes for initial HIVST training, 10 minutes for subsequent HIVST Support 24-hour telephone hotline 98% enrollment into HIVST Serial Algorithm: Determine & Unigold

Option 1. Facility-based HIV testing Option 1: Standard facility-based testing algorithm using Determine, Unigold and ELISA test (no HIV self-testing). In this model HIV negative users on PrEP re-test for HIV in a facility every 3 months.

Option 2. Supervised HIVST in a facility Facility-based supervised HIV self-testing where users self-test in a private place within a facility every 3 months. Less counselling, health worker simply provides support as needed. Individuals with a reactive (positive) self-test result re-test as detailed in Option 1.

Option 3: Unsupervised HIVST & facility-based HIV testing Alternating between quarterly (every 3 months) in- clinic facility-based test and at-home self-test. Reactive (positive) self-tests re-test in a facility (see Option 1). In one year: client visits facility every 6 months

Annual Cost per Person as Cost of HIVST Kit Changes HIVST kits in Kenya cost ~10USD HIVST kits cost ~3USD in Malawi

Annual HIV re-testing cost with PrEP implementation in Kenya per person $3 per HIVST Kit

Sensitivity Analysis for Annual Re-Testing Cost per Person Supervised HIVST Cost of HIVST Kit HW time per facility visit (min) $1$2$3$4$5$6$7$8$9$10 10 $ 37 $42 $47 $52 $ 57 $62 $67 $72 $77 $ $ 43 $48 $53 $58 $ 63 $68 $72 $77 $82. $87 20 $ 49 $54 $59 $63 $ 68 $73 $78 $83 $88 $ $ 54 $59 $64 $ 69 $ 74 $79 $84 $89 $94 $ $ 60 $65 $70 $ 75 $ 80 $85 $89 $94 $99 $ 104 Green = Least expensive of three options Orange = Less expensive than facility-based testing White = Facility-Based is least expensive

Sensitivity Analysis for Annual Re-Testing Cost per Person Unsupervised HIVST Cost of HIVST Kit HW time per facility visit (min) $1$2$3$4$5$6$7$8$9$10 10 $ 31 $34 $36 $39 $42 $45 $48$51 54 $ $ 41 $44 $47 $50 $53 $56 $59 62$65 $ $ 52 $55 $58 $61 $64 $67 $70$73$76 $ $ 63 $66 $69 $72 $75 $77 $80$83$86 $ $ 74 $76 $79 $82 $85 $88 $91 94$97 $100 Green = Least expensive of three options Orange = Less expensive than facility-based testing White = Facility-Based is least expensive

Key Findings Re-testing with HIVST could be less costly than current facility-based re-testing Annual re-testing with HIVST costs less than facility- based re-testing when: –HIVST kit is ≤5USD (supervised HIVST) –HIVST kit is ≤3USD (unsupervised HIVST) Other re-testing scenarios using HIVST may also lead to cost-savings

Key Findings HIVST kits are expensive, but health worker time is more expensive. –Decreasing the amount of health worker time & cost of test kits can significantly reduce costs per person –Sensitivity analysis shows many scenarios where HIVST (supervised & unsupervised) can be less expensive

Limitations Preliminary costing exercise Only factored in re-testing cost, not additional services –Did not factor in opportunity cost, public health benefit, other potential risks & benefits of re-testing with HIVST –Other scenarios of HIVST are possible –Only examined 1 st year of re-testing costs Questions remain about who and how many will be eligible for re-testing using HIVST –Who is most likely to benefit and how will providers identify who is eligible?

Conclusion & Next Steps Introducing supervised or unsupervised HIVST could: –Reduce number of facility visits –More private, convenient way to re-test –Reduce re-testing costs HIVST kit cost ≤3USD to significantly reduce re-testing costs. Research is needed to explore the cost-effectiveness of introducing HIVST within PrEP programmes –Analyses factoring opportunity costs, public health impact, and other potential risks and benefits.

Acknowledgements Kathryn Curran, Kenneth Ngure, Rachel Baggaley, Jared Baeten, Nelly Mugo, Renee Heffron, Kevin O’Reilly, and Florence Koechlin

Standard WHO Serial Algorithm Low prevalence ( < 5%) High prevalence ( < 5%)

Option 1: Facility-based re-testing Facility HTC every 3 months Diagnosis, stop PrEPContinue PrEP DeterminePositive Elisa Unigold Negative PositiveNegative National Testing Algorithm

Option 2: Facility-based Supervised HIVST HIVST Training Facility-based HIVST re-testing every 3 months PositiveNegative Serial Algorithm: Determine & Unigold (see option 1) Continue PrEP

Option 3: Facility-based Unsupervised HIVST HIVST Training Facility HTC re-testing every 3 months PositiveNegative Diagnosis, stop PrEP Continue PrEP HIVST retest 3 months Facility HTC: Serial Algorithm: Determine & Unigold (option 1) Home HIVST re-testing every 3 months NegativePositive Continue PrEP facility HTC retest 3 months